

3. (Amended) The therapeutic agent of claim 1, wherein the therapeutic agent is a QOL improving agent for alleviating a symptom of a disease caused by PTH or PTHrP.

4. (Amended) The therapeutic agent of claim 1, wherein the therapeutic agent is for a syndrome associated with malignancy caused by PTHrP.

5. (Amended) The therapeutic agent according to claim 4, wherein the syndrome associated with malignancy is chosen from at least one of digestive system disorders, proteometabolism abnormality, saccharometabolism abnormality, lipid metabolism abnormality, anorexia, hematological abnormality, electrolyte abnormality, immunodeficiency and pain.

6. (Amended) The therapeutic agent according to claim 1, wherein the disease is chosen from at least one of

a) a secondary hyperparathyroidism caused by PTH and

b) a primary hyperparathyroidism caused by PTH.

7. (Amended) The therapeutic agent of claim 1, wherein the therapeutic agent is for a central nervous system disease caused by PTH or PTHrP.

8. (Amended) The therapeutic agent according to claim 7, wherein the central nervous system disease is chosen from at least one of dyssomnia, neuropathy, nervous symptom disorder, brain metabolism abnormality, cerebral circulation abnormality, autonomic imbalance, and endocrine system abnormality with which central nervous system is associated.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1500 L Street, NW  
Washington, DC 20005  
202 400 4000  
Fax 202 400 4400  
www.finnegan.com

9. (Amended) The therapeutic agent of claim 1, wherein the therapeutic agent is for a disease caused by PTH or PTHrP-cytokine cascade.

10. (Amended) The therapeutic agent according to claim 9, wherein the cytokine is chosen from IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL13, IL- 15, G-CSF, GM-CSF, M-CSF, EPO, LIF, TPO, EGF, TGF-  $\alpha$ , TGF-  $\beta$ , FGF, IGF, HGF, VEGF, NGF, activin, inhibin, a BMP family member, TNF and IFN.

11. (Amended) The therapeutic agent according to claim 9, wherein the disease caused by PTH or PTHrP-cytokine cascade is chosen from at least one of septicemia, cachexia, inflammation, hemopathy, calcium metabolism abnormality, and autoimmune disease.

12. (Amended) The therapeutic agent of claim 1, wherein the therapeutic agent is a central nervous system regulator.

13. (Amended) The therapeutic agent of claim 1, wherein the therapeutic agent is a cytokine network regulator.

15. (Amended) The agent according to any one of claims 1 to 13, wherein the substance that binds to a ligand of PTH receptor or PTHrP receptor to inhibit binding between the ligand and the receptor is chosen from an anti-PTHrP antibody and anti-PTH antibody.

16. (Amended) The agent according to claim 15, wherein the substance that binds to a ligand of PTH receptor or PTHrP receptor to inhibit binding between the ligand and the receptor is an anti-PTHrP antibody.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1500 I Street, NW  
Washington, DC 20005  
202 408 4000  
Fax 202 408 4400  
www.finnegan.com